Alzamend Neuro (ALZN) Share-based Compensation (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Share-based Compensation came in at $623811.0 in Q2 2026, up 667.51% year-over-year from $81277.0 in Q2 2025, and up 355.47% quarter-over-quarter from $136960.0 in Q1 2026.
Powered by 
Analysis
Alzamend Neuro (ALZN) Share-based Compensation (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Share-based Compensation across 7 years of filings, most recently posting $623811.0 for Q2 2026.
- In Q2 2026, Share-based Compensation rose 667.51% year-over-year to $623811.0; the TTM figure through Apr 2026 stood at $829267.0 (down 56.62% YoY), while the FY2026 annual figure was $1.6 million, up 390.12% from the prior year.
- Share-based Compensation came in at $623811.0 for Q2 2026 at Alzamend Neuro, up from $136960.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $18.0 million in Q1 2022 to a low of $16000.0 in Q4 2025.
- Average Share-based Compensation over 5 years is $4.6 million, with a median of $557568.5 recorded in 2023.
- Year-over-year, Share-based Compensation jumped 3029.74% in 2022 and tumbled 99.36% in 2024.
- Over 5 years, Share-based Compensation stood at $14.3 million in 2022, then plunged by 93.15% to $980000.0 in 2023, then plunged by 90.34% to $94667.0 in 2024, then slumped by 83.1% to $16000.0 in 2025, then soared by 3798.82% to $623811.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $623811.0 in Q2 2026, $136960.0 in Q1 2026, and $16000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Alzamend Neuro | 5.54 Mn | 5.54 Mn | - | 623,811.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 623,811.00 |
| Jan 31, 2026 | 136,960.00 |
| Oct 31, 2025 | 16,000.00 |
| Jul 31, 2025 | 42,902.00 |
| Apr 30, 2025 | 81,277.00 |
| Jan 31, 2025 | 94,667.00 |
| Oct 31, 2024 | 94,667.00 |
| Jul 31, 2024 | 94,667.00 |
| Apr 30, 2024 | 81,277.00 |
| Jan 31, 2024 | 980,000.00 |
| Oct 31, 2023 | 980,000.00 |
| Jul 31, 2023 | 14.81 Mn |
| Apr 30, 2023 | 491,326.00 |
| Jan 31, 2023 | 15.31 Mn |
| Oct 31, 2022 | 14.31 Mn |
| Jul 31, 2022 | 14.60 Mn |
| Apr 30, 2022 | 1.26 Mn |
| Jan 31, 2022 | 18.00 Mn |
| Oct 31, 2021 | 19.00 Mn |
| Jul 31, 2021 | 20.50 Mn |